Ionis (IONS) Q4 2025 earnings review
Commercial Pivot Succeeds, But Milestone Reliance and OpEx Weigh on Bottom Line
Ionis finished 2025 with a striking validation of its commercial capabilities. TRYNGOLZA generated $50M in Q4—a 56% sequential jump—pushing full-year sales to $108M and blowing past initial expectations. Commercial revenue as a whole surged 64% YoY in Q4. However, the top-line narrative masks underlying financial volatility: total Q4 revenue actually fell 11% YoY due to lumpy R&D payments, while GAAP net loss more than doubled to $229M as commercial investments swelled. Management's 2026 guidance projects ~20% underlying growth but anticipates operating losses remaining elevated above $500M, testing investor patience for the 2028 cash flow breakeven target.
🐂 Bull Case
TRYNGOLZA's rapid adoption proves Ionis can successfully market its own drugs. With the much larger olezarsen sHTG market launch looming and DAWNZERA gaining early momentum, the commercial foundation is solid.
The pipeline is rapidly de-risking. sNDA is submitted for olezarsen in sHTG, zilganersen NDA is submitted for Alexander disease, and partnered bepirovirsen hit Phase 3 primary endpoints for Hepatitis B.
🐻 Bear Case
Q4 operating expenses spiked to $418M, driving a severe $(229)M net loss. With FY26 non-GAAP operating losses guided at $500-$550M, the company is burning significant cash to fund its commercial transition.
SPINRAZA royalties, long the bedrock of Ionis's non-dilutive cash flow, fell 16% YoY in Q4. If this cash cow dries up faster than expected, it puts immense pressure on the new launches to fund the pipeline.
⚖️ Verdict: ⚪
Neutral. The commercial execution on TRYNGOLZA is genuinely impressive and de-risks the massive sHTG opportunity. However, reversing legacy royalties and heavily elevated near-term cash burn mean the transition to sustainable profitability is still years away.
Key Themes
TRYNGOLZA Launch Demonstrates Exceptional Momentum
TRYNGOLZA sales are accelerating rapidly, jumping from $6M in Q1 to $50M in Q4. This execution completely validates the company's shift to an independent commercial stage, easily beating repeatedly upgraded FY25 guidance ($108M actual vs initial $75-$80M estimates). This bolsters confidence for the upcoming, much larger olezarsen sHTG launch.
Data Contradiction: Headline Success Masks Q4 Revenue Decline
Despite management celebrating a 'defining year' and record product sales, total Q4 revenue actually reversed, falling 11% YoY ($203M vs $227M). This occurred because Collaborative Agreement Revenue plummeted from $97M to $52M YoY. It highlights a structural concern: Ionis's top line remains highly sensitive to unpredictable R&D milestone timings, which currently dictate whether the company prints growth or contraction.
SPINRAZA Royalties Decelerating
A worrying trend is cementing in the legacy portfolio: SPINRAZA royalties dropped 16% YoY in Q4 ($54M vs $64M). While high-dose approval in the EU and pending US review may offer a defense, the base business is facing intense competitive pressure. This erosion threatens a vital funding source for Ionis's commercial buildout.
Blockbuster sHTG Opportunity Nears
The sNDA for olezarsen in severe hypertriglyceridemia (sHTG) has been submitted. Targeting over 1 million high-risk patients in the U.S., this represents a multi-billion dollar TAM. The drug's unique mechanism—demonstrating an 85% reduction in acute pancreatitis events during Phase 3 CORE trials—provides a critical competitive moat.
Olezarsen Pricing Transition Strategy
A major upcoming hurdle is managing the pricing paradigm shift for olezarsen. Currently priced for the ultra-rare FCS market (approx. 3,000 U.S. patients), the label expansion into sHTG (>1 million patients) will necessitate a substantial price reduction. How payers react and how Ionis manages the volume-for-price trade-off will dictate near-term revenue dynamics.
Partner Pipeline Yielding Results
WAINUA royalties are accelerating, reaching $16M in Q4 (up 60% YoY) and $49M for the year. Furthermore, the partner pipeline hit a massive milestone with bepirovirsen achieving its Phase 3 primary endpoint for Chronic Hepatitis B, setting up global regulatory filings in Q1 2026.
Alexander Disease Execution Risk
Zilganersen is on track for a 2026 launch with an NDA submitted. However, as the first-ever disease-modifying therapy for the rare and fatal Alexander disease, it carries high first-mover regulatory and commercialization uncertainty, specifically regarding payer education and patient identification.
Other KPIs
Accelerating. Grew 64% YoY ($141M vs $86M) and now constitutes 69% of total Q4 revenue, proving the success of the company's pivot from a milestone-dependent R&D shop to a true commercial entity.
Accelerating. Grew 14% YoY from $1.05B in FY24. The step-up was fully anticipated as the company aggressively scaled its sales force and marketing infrastructure for TRYNGOLZA, DAWNZERA, and WAINUA launches, but it severely limits near-term profitability.
Stable. Up from $2.30B at the end of 2024. The increase is primarily due to refinancing proceeds from the recent convertible debt issuance, which will be utilized to repay the $629M in 2026 Convertible Notes currently sitting on the balance sheet.
Guidance
Decelerating on a reported basis, but Accelerating on an underlying basis. The headline figure drops from FY25's $944M, but FY25 included a massive one-time $280M upfront payment for sapablursen. Adjusting for that anomaly, the $812.5M midpoint implies a robust ~22% YoY underlying growth rate.
Stable compared to the adjusted FY25 baseline. While FY25 reported a $248M loss, stripping out the $280M sapablursen upfront reveals an underlying FY25 loss of ~$528M. Management is essentially guiding for sustained, heavy commercial investment that neutralizes gross profit gains.
Decelerating. Represents a steep drop from the current $2.7B balance, largely reflecting the planned repayment of the 2026 Convertible Notes and funding the projected operating losses. Keeps the company funded through its 2028 cash-flow breakeven target.
Key Questions
Olezarsen Pricing Strategy
With the sNDA for sHTG submitted, how and when will the company navigate the pricing step-down from the ultra-rare FCS indication to the broader >1M patient sHTG population without causing sudden revenue air pockets?
SPINRAZA Royalty Degradation
SPINRAZA royalties declined 16% YoY this quarter. How much of this is structural market share loss versus inventory timing, and realistically, how much can the high-dose approval offset this trend in 2026?
Cash Breakeven Assumptions
Given the guidance for ~$500M+ in adjusted operating losses and an ending 2026 cash balance of $1.6B, does the 2028 cash-flow breakeven target implicitly assume further non-dilutive milestone windfalls, or can product revenue alone bridge the gap?